SCHEMBL703707

SCHEMBL703707

Cc1nc2cc(NCCN(C)C)ccn2c1-c1ccnc(Nc2ccc(C(=O)NO)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.47
CDK4 P11802 3/20 0.47
CCNE1 P24864 2/20 0.47
CDK1 P06493 2/20 0.47
IKBKB O14920 1/20 0.47
CHUK O15111 1/20 0.47
IKBKG Q9Y6K9 1/20 0.47
CDC7 O00311 1/20 0.46
CDK19 Q9BWU1 1/20 0.46
CCNT1 O60563 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK9 P50750 1/20 0.44
CCNA1 P78396 1/20 0.44
CAMK2D Q13557 1/20 0.43
HDAC1 Q13547 6/20 0.43
IGF1R P08069 2/20 0.43
FLT3 P36888 1/20 0.42
SYK P43405 1/20 0.42
HDAC3 O15379 1/20 0.42
JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712740 0.92 CDK2 (0.50) CDK2CDK4CCNE1CDK1IKBKB
SCHEMBL700392 0.87 HDAC1 (0.61) CDK2CDK4CCNE1CDK1IKBKB
SCHEMBL699248 0.86 IGF1R (0.53) CDK2CDK4CCNE1CDK1IKBKB
SCHEMBL700744 0.86 CDK2 (0.49) CDK2CDK4CCNE1CDK1
SCHEMBL658588 0.83 HDAC1 (0.36) CDK2CDK4CCNE1CDC7CDK19
SCHEMBL701721 0.83 CDK2 (0.55) CDK2CDK4CCNE1CDK1IKBKB
SCHEMBL700183 0.83 IKBKB (0.53) CDK2CDK4CCNE1CDK1IKBKB
SCHEMBL699170 0.82 CDK2 (0.50) CDK2CDK4CCNE1CDK1CAMK2D
SCHEMBL699629 0.81 CDK2 (0.51) CDK2CDK4CCNE1CDK1CAMK2D
SCHEMBL699814 0.81 CDK2 (0.51) CDK2CDK4CCNE1CDK1CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124764-B2 Fused heterocyclyc inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-02-28 US claimed
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-02-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029638-A1 FUSED HETEROCYCLYC INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC7 CDK2 16/4885CDK4 15/4885CCNE1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.